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Research Submission
Long-Term Safety Evaluation of Ubrogepant for the Acute
Treatment of Migraine: Phase 3, Randomized, 52-Week
Extension Trial
Jessica Ailani, MD; Richard B. Lipton, MD; Susan Hutchinson, MD; Kerry Knievel, DO; Kaifeng Lu, PhD;
Matthew Butler, MD; Sung Yun Yu, BA; Michelle Finnegan, MPH; Lawrence Severt, MD;
Joel M. Trugman, MD

Objective.—To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine.
Background.—Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of
migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in
migraine headache pain, migraine-associated symptoms, and ability to function.
Methods.—This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or
without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care,
ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care
continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the
primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received
at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3
times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose.
Results.—The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant
100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90% (1106/1230) female and
85% (1043/1230) white, with an average BMI of 30 kg/m2. Throughout the trial, 21,454 migraine attacks were treated with
31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66%) participants receiving
ubrogepant 50 mg and 297/409 (73%) receiving ubrogepant 100 mg. The most commonly reported TEAE was upper respiratory
tract infection (<12%); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10%)
participants in the ubrogepant 50-mg group and 43/409 (11%) in the ubrogepant 100-mg group. Serious adverse events (SAEs)
were reported by 9/404 (2%) participants in the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg
group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent
clinical adjudication committee of liver experts. There were no cases of Hy’s Law.
Conclusions.—Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute
treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and
discontinuations due to adverse events in this 1-year trial.
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Abbreviations: A
 LT alanine aminotransferase, AST aspartate aminotransferase, CGRP calcitonin gene-related peptide,
ECG electrocardiogram, IWRS interactive Web response system, NSAIDs non-steroidal anti-inflammatory
drugs, SAE serious adverse event, TEAE treatment-emergent adverse event
(Headache 2020;60:141-152)

INTRODUCTION
Migraine is a highly prevalent and burdensome
chronic disease with attacks characterized by 1-sided
pulsatile pain associated with sensitivity to light and
sound, and nausea in various combinations.1 Based on
the recent Global Burden of Disease study, migraine
ranks second among the leading causes of years lived
with disability,2,3 impacting not only a person’s daily
living activities but having a negative effect on their
families as well.4-9 Effective and safe treatment options
are needed to help reduce the burden of migraine.
Several acute treatment options are currently
available, including analgesics, nonsteroidal antiinflammatory drugs (NSAIDs), ergot derivatives, and
triptans.10-12 Even with the number of acute treatments available, approximately 50% of those with migraine are not satisfied with their acute treatment for
migraine and most have significant unmet treatment
needs.13 In the Migraine in America Symptoms and
Treatment study,14 of the 15,133 adults with migraine,
only 15% were using a triptan and 95.8% had at least
1 unmet treatment need.15 Among migraine-specific

acute medications, ergot derivatives and triptans,
though effective, are associated with safety and tolerability issues as well as contraindications.11,16 This
supports the need for additional migraine-specific
treatment options with desirable efficacy and safety
profiles.
Calcitonin gene–related peptide (CGRP) plays an
important role in migraine pathophysiology and as
a result, small molecule CGRP receptor antagonists,
known as gepants, are being studied for their efficacy in
treating migraine.17,18 Ubrogepant is an oral gepant in
development for the acute treatment of migraine. The
efficacy and safety of ubrogepant have been shown
in proof-of-concept and large, placebo-controlled trials.19-21 The phase 3 ACHIEVE I and II single-attack
trials met their co-primary endpoints for the 50- and
100-mg doses, thereby establishing ubrogepant’s efficacy. Rates of headache pain freedom 2 hours post-dose
were significantly superior to placebo with ubrogepant
25, 50, and 100 mg (P ≤ .01).20,21 In addition, the rates
of absence of the most bothersome migraine-associated symptom (photophobia, phonophobia, or nausea)
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at 2 hours were significantly greater with ubrogepant
50 and 100 mg than placebo (P ≤ .01), but not with
ubrogepant 25 mg.
The primary objective of this phase 3, multicenter,
randomized, 52-week extension trial was to evaluate
the long-term safety and tolerability of intermittent
treatment with ubrogepant for the acute treatment
of migraine over 1 year. Treatment groups included
ubrogepant 50 mg, ubrogepant 100 mg, and a usual
care arm. The usual care arm was included to contextualize any hepatic safety findings over the course of
this trial. Many treatments were included in the usual
care arm, often treatments the patients were already
using; therefore, non-laboratory adverse events (AEs)
were not captured in relation to treatment in this arm.

METHODS
Trial Design.—This was a phase 3, multicenter,
randomized, open-label, 52-week extension trial conducted at 161 centers in the United States. The trial protocol and all amendments were approved by
properly constituted local and central institutional
review boards. All participants provided written informed consent before initiation of any trial-specific
procedures. The trial was sponsored by Allergan plc,
which included provision of trial treatment for those
randomized to ubrogepant treatment arms. Changes
to the original protocol are in Supplementary S1.
The first participant was enrolled September
13, 2016 and the last participant completed August
2, 2018. Participants were identified by the trial investigator and entered the trial after completing one
of 2 randomized, double-blind, placebo-controlled,
single-attack, phase 3 lead-in trials (ACHIEVE I,
NCT02828020; ACHIEVE II, NCT02867709) and
were re-randomized 1:1:1 to usual care, ubrogepant
50 mg, or ubrogepant 100 mg.
Participants who were on a stable dose of migraine preventive medication were allowed to continue on their medication. Those with an alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥1.5 times the upper limit of normal (ULN) or bilirubin >1.5 mg/dL at screening were
not included. Participants could not have any clinically significant abnormalities in their electrocardiogram (ECG), physical examination, or laboratory
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test and could not have uncontrolled hypertension.
Those with clinically significant cardiovascular or
cerebrovascular disease or myocardial infarction,
transient ischemic attack, or stroke within 6 months
prior to Visit 1 were excluded from the trial. Use of
moderate to strong CYP3A4 inhibitors and inducers
was prohibited during the trial.
Although this was an open-label trial, randomization to the ubrogepant dose was blinded. Participants
randomized to ubrogepant took 2 tablets to treat each
migraine attack. Participants in the ubrogepant 100-mg
arm took two 50-mg ubrogepant tablets, whereas participants in the ubrogepant 50-mg arm took 1 ubrogepant
50-mg tablet and 1 placebo tablet. Participants randomized to ubrogepant could treat up to 8 migraine attacks per 4-week interval during the 1-year trial period.
If participants returned to the site and received study
medication prior to the end of a designated 4-week
interval, they could treat more than 8 migraine attacks
in a 4-week interval. Participants could treat headache
pain of any severity (ie, mild, moderate, or severe). A
qualifying migraine attack must have met all of the following conditions: at least 48 hours had passed since
the last dose of ubrogepant, the participant had at least
48 hours of pain freedom, less than 4 hours had passed
since the headache started, the headache was not
resolving on its own, and prohibited medications were
not taken.
An optional second dose of ubrogepant or rescue
medication, which could include analgesics (eg, acetaminophen, NSAIDs, opioids), anti-emetics, or triptans, was allowed at least 2 hours after the initial dose
if the participant had a nonresponding migraine or
migraine recurrence. The second dose of ubrogepant
was the same as the first dose and could be taken
2–48 hours after the initial ubrogepant dose. If a second dose was taken, the participant was not allowed to
take rescue medication for at least 2 hours after the second dose. If the participant opted to take rescue medication instead, an optional second dose of ubrogepant
was not allowed. Participants randomized to the usual
care arm continued to treat their migraine attacks
with medication that they had been taking historically.
Their usual care medications were identified at Visit 1
and any changes were recorded in the electronic case
report form.
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After screening and randomization, visits occurred
every 4 weeks for 1 year. The clinic visits for safety assessments were at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44,
48, and 52 weeks relative to the randomization visit.
A safety follow-up visit occurred 4 weeks after the
52-week visit or after early termination. Participants
who did not treat a single migraine attack in the first
6 months of the trial were discontinued.
An automated interactive Web response system
(IWRS) was used to manage the randomization and
treatment assignment. The sponsor’s biostatistician
prepared the randomization codes. Investigational
product was labeled with medication kit numbers.
The IWRS provided the site with the specific medication kit number for each randomized participant
in the ubrogepant arms at the time of randomization.
Randomization was stratified by the participant’s
historical triptan response and current preventive
concomitant medication use, as determined in the leadin trials. All participants, site personnel, and trial sponsor personnel were blinded to ubrogepant dose in this
open-label trial.
An interim analysis was planned for when at least
300 ubrogepant-treated participants who treated
an average of ≥2 migraine attacks per month were
enrolled in the trial for 6 months and 200 ubrogepant-treated participants who treated an average of ≥2
migraine attacks per month were enrolled for 1 year.
At the time of the interim database lock, the ubrogepant dosing assignments were unblinded to the sponsor; participants and investigators remained blinded.
A full data analysis was conducted after trial completion and the data from the final 1-year trial are
reported here.
Outcome Measures.—The primary outcomes
were safety and tolerability, which included collection of AEs, clinical laboratory determinations, ECGs,
vital sign measurements, physical examinations, and the
Columbia-Suicide Severity Rating Scale at each clinic visit. Investigators began each visit by querying for
AEs by asking the participant a general, non-directed
question such as “How have you been feeling since the
last visit?” and then followed up with directed questioning, examination, and documentation, as appropriate.
All AEs were coded using the Medical Dictionary for
Regulatory Activities version 20.1 by the sponsor’s med-
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ical coding group. The investigators were required to
provide an assessment of the severity, the likelihood of
a causal relationship to the study medication, and seriousness of the event, document all actions taken with
regard to the study medication, and detail any other
treatment measures taken for the AE.
An independent clinical adjudication committee
of liver experts was established for blinded adjudication of posttreatment elevations of ALT and/or AST
≥3 times the ULN. Potential Hy’s Law cases were defined as an elevation of ALT or AST value ≥3× the
ULN and an elevated total bilirubin value ≥2× ULN,
and, at the same time, an alkaline phosphatase value
<2× ULN, all based on blood draws collected within
a 24-hour period.22,23 A data safety monitoring board
monitored unblinded safety data. Exploratory efficacy
assessments of headache severity, migraine-associated
symptoms (photophobia, phonophobia, nausea, and
vomiting), use of rescue medications, use of optional
second dose, and recurrence of headache pain were
collected for ubrogepant treatment arms only. This
manuscript’s focus is the safety outcomes; thus a comprehensive summary of efficacy findings will be reported separately.
Statistical Analysis.—The sample size was driven by
regulatory safety requirements for duration of exposure and number of participants rather than statistical
considerations. The expected randomization was 1200
participants with at least 70% completing 12 months of
treatment and at least 50% expected to treat on average
at least 2 migraine attacks per month.
The screened population included all screened
participants who signed the informed consent. The
intent-to-treat population included all randomized
participants. The safety population included all randomized participants who took at least 1 dose of
ubrogepant treatment and all participants randomized
to the usual care arm.
AE data were analyzed by calculating the frequency and percentage of participants reporting the
event in each treatment group. No formal statistical
comparisons between treatment groups were planned
or executed. The usual care population was included
only to contextualize background rates of ALT/AST
safety findings occurring in the ubrogepant-treated
participants. Elevations of ALT/AST are often
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asymptomatic; thus, the usual care arm provided withinstudy control of natural fluctuations in these evaluations within a migraine population. The usual care
population included participants who had been on and
had tolerated their medication prior to enrollment. The
participants in the usual care arm selected their usual
acute treatment for migraine based on their prior treatment experience; therefore, direct comparisons of AE
rates between ubrogepant and the usual care arm cannot be made given this self-selection. Many of the usual
care arm participants had a history of tolerating their
selected medication; therefore, AE rates in the usual
care arm would not have reflected the introduction of
a new treatment, as they did in the ubrogepant arms.
Because previous experience with the usual care drug
could have reduced the probability of experiencing
/reporting safety or tolerability AEs, AEs reported in
the usual care arm were not assessed for relatedness
to the usual care medication. To directly evaluate the
safety and tolerability profiles of acute treatments,
enrolled participants should be naïve to each treatment
before randomization, after which AE profiles can be
compared.
AEs occurring after the screening visit were
summarized for treatment-emergent adverse events

Fig. 1.—Participant disposition.
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(TEAEs), treatment-related TEAEs, serious adverse
events (SAEs), and AEs leading to discontinuation.
Treatment-related TEAEs were only determined for
ubrogepant treatment arms.
Clinical laboratory assessments were summarized by
treatment group. The adjudication committee findings
were summarized by treatment group for participants
with ALT or AST elevations ≥3 times the ULN.
Statistical analyses were conducted using SAS
Version 9.4 or later (Cary, NC).

RESULTS
Participants and Extent of Exposure.—In this trial,
1310 participants were screened, 1254 randomized, and 1230 included in the safety population
(Fig. 1). Of the safety population, 665 participants were
from the ACHIEVE I lead-in trial and 565 from the
ACHIEVE II lead-in trial. In the ubrogepant 50-mg
group, 404 participants treated 10,323 migraine attacks with 1 or more doses of ubrogepant for a total of
15,536 doses. In the ubrogepant 100-mg group, 409
participants treated 11,131 migraine attacks with 1 or
more doses of ubrogepant for a total of 16,432 doses.
Over the course of the trial, an average of 13.2 and 14.8
migraine attacks were treated with 1 dose of ubrogepant
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50 and 100 mg, respectively, and an average of 12.3 and
12.4 migraine attacks were treated with 2 or more
doses of ubrogepant 50 and 100 mg, respectively.
The average number of doses taken per participant
over the 1-year trial period was 38.5 doses for ubrogepant
50 mg and 40.2 doses for ubrogepant 100 mg.
Considering the maximum number of treated attacks
in any given month, a total of 233 (29%) ubrogepanttreated participants treated 6 or more migraine attacks
during at least 1 month in the trial (109 participants in
the ubrogepant 50-mg group and 124 participants in
the ubrogepant 100-mg group). Of these, a total of 72
(9%) participants treated 8 or more migraine attacks
in at least 1 month (30 participants in the ubrogepant 50-mg group and 42 in the ubrogepant 100-mg
group). Cumulatively, participants treated 6 or more
migraines in a month in 740 months (334 months for
those who took ubrogepant 50 mg and 406 months
for those who took ubrogepant 100 mg). Participants
treated 8 or more migraine attacks in a month for a
total of 144 months (55 months for those who took
ubrogepant 50 mg and 89 months for those who took
100 mg).
Demographics and Clinical Characteristics.—In the
safety population, participants were on average
41.8 years of age (SD = 11.7), predominantly female
(N = 1106/1230, 90%) and white (N = 1043/1230, 85%),
with an average BMI of 29.9 kg/m2 (SD = 7.7). At the
time of randomization, 306 (24.9%) participants in the
safety population were on a preventive treatment for
migraine (eg, topiramate, onabotulinumtoxinA, propranolol, amitriptyline), and use of preventive treatment was evenly distributed across treatment groups
(n = 102 [25%] in each group). In the safety population, nearly all participants (99.5%) took at least 1 concomitant medication during the treatment period. The
most common were ibuprofen (54.5%), combination
aspirin-acetaminophen-caffeine (36.4%), sumatriptan
(27.6%), and acetaminophen (25.6%). Overall, participant demographics and clinical characteristics were
similar in the ubrogepant and usual care arms.
Ubrogepant Adverse Events.—TEAEs occurred
in 268 (66%) participants in the ubrogepant 50-mg
group and in 297 (73%) participants in the ubrogepant
100-mg group (Table 1). Most commonly reported
TEAEs (≥2% of participants in any treatment group;
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Table 1.—Overall Summary of Adverse Events
(Safety Population)

TEAEs†
Treatment-related TEAEs†
On therapy SAE‡,§
Deaths‡
AEs leading to discontinuation¶

Ubrogepant
50 mg
n = 404
n (%)

Ubrogepant
100 mg
n = 409
n (%)

268 (66.3)
42 (10.4)
9 (2.2)
0
9 (2.2)

297 (72.6)
43 (10.5)
12 (2.9)
0
11 (2.7)

†Treatment-emergent events were defined as those events that
initially occurred or increased in intensity on or after the initial
dose of treatment of the lead-in trial. An event that occurred
after Visit 16 for participants with Visit 16 or more than 30 days
after the last visit or last treatment, whichever was later, for
participants without Visit 16 was not considered to be treatment
emergent.
‡On-therapy events were defined as those events that occurred
between the treatment start date of the lead-in trial and Visit 16,
or within 30 days after the last visit or last treatment, whichever
was later, for participants without Visit 16.
§All SAEs reported, by preferred term, ubrogepant 50 mg:
cholecystitis acute, cholelithiasis, pneumonia, device allergy
(allergic reaction due to Essure® implant), gait disturbance,
hypertensive crisis, intestinal obstruction, pelvic inflammatory
disease, postprocedural infection, sinus tachycardia, substanceinduced mood disorder; ubrogepant 100 mg: abortion, abortion
spontaneous, acute respiratory failure, cholecystitis acute,
cholelithiasis, colitis, diabetic ketoacidosis, ectopic pregnancy,
gastroenteritis norovirus, hemiparesis, hiatus hernia, non-cardiac
chest pain, pancreatitis acute, pneumonia, sepsis, subdural
hematoma, suicidal ideation.
¶Includes events that occurred from screening to Visit 16, or
within 30 days after the last visit or last treatment, whichever
was later, for participants without Visit 16.
Only events that occurred on or after the randomization date are
included except for AEs leading to discontinuation. Participants
are counted only once within each category.
AE = adverse event; SAE = serious adverse event; TEAE =
treatment-emergent adverse event.

Table 2) were upper respiratory tract infection, nasopharyngitis, sinusitis, urinary tract infection, influenza, and nausea. No increase in the incidence of TEAEs
was noted with an increase in number of attacks treated per month (Supplementary S2). The incidence of
TEAEs was similar across age (Supplementary S3), sex
(Supplementary S4), and race subgroups (Supplementary S5).
Of the participants who had TEAEs, approximately 10% were considered related to ubrogepant
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Table 2.—Common (≥2%)† Treatment-Emergent Adverse
Events by Preferred Term

Preferred Term‡

Nasopharyngitis
Upper respiratory tract infection
Sinusitis
Urinary tract infection
Influenza
Nausea
Bronchitis
Blood creatine phosphokinase
increased
Alanine aminotransferase
increased
Aspartate aminotransferase
increased
Back pain
Nephrolithiasis
Dizziness
Anxiety
Cough
Diarrhea
Arthralgia
Gastroenteritis viral
Muscle strain
Depression
Migraine
Abdominal pain
Epididymitis§
Testicular pain§

Ubrogepant
50 mg
n = 404
n (%)

Ubrogepant
100 mg
n = 409
n (%)

33 (8.2)
47 (11.6)
28 (6.9)
22 (5.4)
17 (4.2)
19 (4.7)
13 (3.2)
10 (2.5)

47 (11.5)
44 (10.8)
26 (6.4)
26 (6.4)
25 (6.1)
19 (4.6)
18 (4.4)
16 (3.9)

9 (2.2)

15 (3.7)

7 (1.7)

14 (3.4)

14 (3.5)
4 (1.0)
5 (1.2)
6 (1.5)
8 (2.0)
10 (2.5)
11 (2.7)
7 (1.7)
2 (0.5)
1 (3.2)
6 (1.5)
4 (1.0)
1 (3.2)
1 (3.2)

14 (3.4)
13 (3.2)
12 (2.9)
11 (2.7)
11 (2.7)
11 (2.7)
10 (2.4)
10 (2.4)
10 (2.4)
5 (1.2)
4 (1.0)
2 (0.5)
0 (0)
0 (0)

†Only adverse events reported in ≥2% of participants (after
rounding) in any treatment group are shown. Participants are
counted only once within each preferred term.
‡Preferred terms were coded according to the Medical Dictionary
of Regulatory Activity (MedDRA) Version 20.1.
§For sex-specific adverse events, percentages are relative to the
number of participants of the appropriate sex.

treatment by the investigator. The most commonly
reported treatment-related TEAEs (≥1%) in any
ubrogepant dose group were nausea (1.5 and 1.7% with
ubrogepant 50 and 100 mg, respectively), dizziness
(0.5 and 1.5%), and somnolence (1.5 and 1.2%). ALT
increases (0.7 and 1.0%) and AST increases (0.5 and
1.0%) also occurred with ubrogepant 50 and 100 mg.
Most TEAEs were mild or moderate in severity.
Severe TEAEs were reported for 6.2 and 8.1% of participants in ubrogepant 50-mg and ubrogepant 100-mg
groups, respectively. Severe TEAEs that were reported
for 3 or more participants in the ubrogepant groups

were AST increase, cholelithiasis, nephrolithiasis, pneumonia, and sinusitis (each reported for 3 ubrogepanttreated participants); influenza, migraine, and nausea
were each reported for 4 ubrogepant-treated
participants.
SAEs were reported for 9/404 (2%) participants in
the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg group (Table 1). Only
1 SAE was considered related to treatment by the investigator (sinus tachycardia), and this event occurred
in a participant with a history of supraventricular
tachycardia with ablation; the participant continued
to take ubrogepant after this event without further
complications. No deaths occurred during the trial.
Discontinuations due to AEs were reported for 2–3%
of the ubrogepant-treated participants. TEAEs leading
to discontinuation assessed as related to treatment by
the investigator were reported for 4 participants in
the ubrogepant 50-mg group (nausea, thrombocytopenia, urticaria, and vomiting) and 4 in the ubrogepant
100-mg group (abnormal ECG and extrasystolic beats;
nausea and palpitations; pruritus; ALT and AST increase). The event of thrombocytopenia was reported as
unknown in terms of relatedness and imputed as related.
Cardiovascular Safety.—Frequency of cardiovascular TEAEs in predefined categories of cardiac
arrhythmia, central nervous system (CNS) vascular
disorders, embolic and thrombotic events, hypertension, and ischemic heart disease were generally balanced between ubrogepant treatment groups
(Table 3). No cardiovascular TEAEs occurred at a
rate >2% in either ubrogepant treatment arm; few
cardiovascular SAEs were reported. Two SAEs were
reported in the category of CNS vascular disorders,
both considered not related to study medication. One
event was an SAE of hemiparesis; vascular etiology
(ie, stroke) was ruled out and the investigator considered the event to be due to poorly controlled hypothyroidism (Supplementary S6). The other SAE was
a traumatic subdural hematoma due to a head injury.
One cardiovascular SAE was considered related
to treatment by the investigator (sinus tachycardia,
details presented in Ubrogepant Adverse Events section). No cardiovascular events related to myocardial infarction or stroke were reported in either ubrogepant
treatment arm.

148

January 2020

Table 3.—Treatment-Emergent Cardiovascular Adverse
Events of Special Interest

TEAE Category†
Preferred Term

Cardiac arrhythmias
Arrhythmia
ECG QRS complex prolonged
Extrasystoles
Sinus tachycardia‡
Ventricular extrasystoles
Atrioventricular block first degree
Cardiac flutter
Sinus bradycardia
CNS vascular disorder/embolic and
thrombotic events
Hemiparesis†,‡,§
Traumatic subdural hematoma‡
Hypertension
Hypertension
Blood pressure diastolic increased
Blood pressure increased
Hypertensive crisis‡
Prehypertension
Ischemic heart disease
Angina pectoris

Ubrogepant Ubrogepant
100 mg
50 mg
n = 409
n = 404
n (%)
n (%)

4 (1.0)
0
0
0
1 (0.2)
0
1 (0.2)
1 (0.2)
1 (0.2)
0

5 (1.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.5)
0
0
0
2 (0.5)

0
0
13 (3.2)
8 (2.0)
1 (0.2)
3 (0.7)
1 (0.2)
1 (0.2)
2 (0.5)
2 (0.5)

1 (0.2)
1 (0.2)
11 (2.7)
7 (1.7)
2 (0.5)
2 (0.5)
0
0
2 (0.5)
2 (0.5)

†Each category is based on predefined standard groups of
Preferred Terms (narrow Standard MedDRA Queries).
‡Reported as a serious adverse event.
§The participant with hemiparesis had negative imaging for any
vascular events and stroke was ruled out as a possible cause.
The investigator attributed the event to severe uncontrolled
hypothyroidism.
CNS = central nervous system; TEAE = treatment-emergent
adverse event.

Hepatic Safety.—The mean changes in ALT and
AST from baseline to postbaseline visits were similar
across the ubrogepant treatment groups and the usual care arm (Supplementary S7). Postbaseline hepatic
laboratory values of clinical interest are presented in
Table 4. There were no cases of confirmed Hy’s Law.
One participant, while hospitalized with recurrent
acute cholecystitis due to gallstones seen in the common bile duct, had rapid rises in ALT/AST and bilirubin levels. Following gallbladder removal, enzymes
returned to normal (Supplementary S8). As there
was an underlying cause for these ALT/AST and bilirubin elevations, this case did not meet criteria for
Hy’s Law. Twenty cases of ALT or AST elevations of

≥3× ULN were reported, as follows: 4/398 (1.0%)
in the usual care arm, 5/399 (1.3%) in the ubrogepant
50 mg arm, and 11/406 (2.7%) in the ubrogepant
100 mg arm. All ≥3× ULN ALT or AST cases were
adjudicated by an independent panel of liver experts blinded to ubrogepant dose (Supplementary
S8). Out of the 20 cases, 17 (4 usual care, 3 ubrogepant 50 mg, and 10 ubrogepant 100 mg) were judged
Unlikely Related to study medication. Two cases (both
ubrogepant 50 mg) were judged Possibly Related
with confounding factors reported (increased alcohol and acetaminophen use; dilated bile duct). Only 1
case of ALT or AST elevations of ≥3× ULN (ubrogepant 100 mg) was judged Probably Related; however, confounding factors were noted (prednisone use
for exacerbation of psoriasis prior to rise in ALT/
AST). All cases of ALT or AST elevation ≥3× ULN
resolved in those who continued ubrogepant dosing.
Usual Care Adverse Events.—As noted, the usual
care population was included to examine variability
in hepatic laboratory parameters to help contextualize the hepatic safety data. The trial was not designed
to specifically compare AEs between these groups due
to the differences in the usual care and ubrogepanttreated populations, as outlined above. A total
of 271/417 participants (65.0%) reported a TEAE;
relatedness was not assessed for the usual care arm.
The most common (≥2% participants in any group;
Supplementary S9) were upper respiratory tract infection (n = 48/417, 11.5%), nasopharyngitis (n = 33,
7.9%), sinusitis (n = 25, 6.0%), urinary tract infection (n = 23, 5.5%), and influenza (n = 21, 5.0%).
Severe TEAEs were reported for 6.2% of participants.
Serious AEs were reported by 17 participants (4.1%)
(Supplementary S10). No deaths were reported and 4
participants (1.0%) reported TEAEs that led to discontinuation.

DISCUSSION
This phase 3, long-term safety evaluation followed 813 participants treated intermittently with
ubrogepant 50 or 100 mg over the course of 1 year.
A total of 21,454 migraine attacks were treated with
31,968 doses of ubrogepant. Participants treated
≥8 migraine attacks with ubrogepant 50 or 100 mg
in a total of 144 months. Overall, there was a low
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Table 4.—Hepatic Laboratory Parameters: Postbaseline Values of Clinical Interest (Safety Population)

Preferred Term

ALT (U/L)
≥1 × ULN
≥1.5 × ULN
≥2 × ULN
≥3 × ULN
≥5 × ULN
≥10 × ULN
≥20 × ULN
AST (U/L)
≥1 × ULN
≥1.5 × ULN
≥2 × ULN
≥3 × ULN
≥5 × ULN
≥10 × ULN
≥20 × ULN
ALT or AST (U/L)
≥1 × ULN
≥1.5 × ULN
≥2 × ULN
≥3 × ULN
≥5 × ULN
≥10 × ULN
≥20 × ULN
Bilirubin total (μmol/L)
≥1 × ULN
≥1.5 × ULN
≥2 × ULN
≥3 × ULN
≥5 × ULN
≥10 × ULN
≥20 × ULN
Alkaline phosphatase (U/L)
≥1 × ULN
≥1.5 × ULN
≥2 × ULN
≥3 × ULN
≥5 × ULN
≥10 × ULN
≥20 × ULN
Concurrent elevations†
ALT or AST ≥3× ULN and bilirubin
total ≥1.5× ULN
ALT or AST ≥3× ULN and bilirubin
total ≥2× ULN
Potential Hy's law‡
ALT or AST ≥3× ULN and bilirubin
total ≥2× ULN and ALP <2× ULN

Usual Care
n = 417
n (%)

Ubrogepant 50 mg
n = 404
n (%)

Ubrogepant 100 mg
n = 409
n (%)

114/397 (28.7)
38/397 (9.6)
16/397 (4.0)
4/397 (1.0)
1/397 (0.3)
0/397
0/397

117/399 (29.3)
38/399 (9.5)
14/399 (3.5)
4/399 (1.0)
2/399 (0.5)
0/399
0/399

122/406 (30.0)
55/406 (13.5)
33/406 (8.1)
8/406 (2.0)
4/406 (1.0)
1/406 (0.2)
0/406

60/397 (15.1)
13/397 (3.3)
5/397 (1.3)
2/397 (0.5)
1/397 (0.3)
0/397
0/397

55/399 (13.8)
16/399 (4.0)
9/399 (2.3)
2/399 (0.5)
1/399 (0.3)
0/399
0/399

70/406 (17.2)
28/406 (6.9)
10/406 (2.5)
9/406 (2.2)
4/406 (1.0)
2/406 (0.5)
1/406 (0.2)

123/397 (31.0)
42/397 (10.6)
19/397 (4.8)
4/397 (1.0)
1/397 (0.3)
0/397
0/397

124/399 (31.1)
41/399 (10.3)
20/399 (5.0)
5/399 (1.3)
2/399 (0.5)
0/399
0/399

134/406 (33.0)
59/406 (14.5)
35/406 (8.6)
11/406 (2.7)
6/406 (1.5)
2/406 (0.5)
1/406 (0.2)

14/397 (3.5)
3/397 (0.8)
1/397 (0.3)
0/397
0/397
0/397
0/397

16/399 (4.0)
5/399 (1.3)
3/399 (0.8)
1/399 (0.3)
0/399
0/399
0/399

18/406 (4.4)
2/406 (0.5)
2/406 (0.5)
1/406 (0.2)
0/406
0/406
0/406

35/397 (8.8)
3/397 (0.8)
1/397 (0.3)
0/397
0/397
0/397
0/397

48/399 (12.0)
1/399 (0.3)
1/399 (0.3)
0/399
0/399
0/399
0/399

36/406 (8.9)
1/406 (0.2)
0/406
0/406
0/406
0/406
0/406

0/397

0/399

1/406 (0.2)

0/397

0/399

1/406 (0.2)

0/397

0/399

1/406 (0.2)

†Concurrent elevations are from the same day.
‡One participant met biochemical Hy’s Law criteria due to an episode of acute cholecystitis; however, there were no confirmed Hy’s
Law cases.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal value.
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incidence of TEAEs, which were mostly mild to moderate in severity with the majority considered unrelated to treatment by the investigator. There was no
apparent relationship between TEAE incidence and
the number of attacks treated per month. In addition, no hepatic or cardiovascular safety issues were
noted. Additionally the rates of SAEs and discontinuations due to AEs were low, with less than 3%
of participants treated with ubrogepant experiencing either. Based on these results, long-term, intermittent use of ubrogepant for the acute treatment of
migraine appears to be safe and well tolerated.
Previously, the gepant class had been evaluated
for their efficacy and safety in the acute treatment of
migraine and showed promising efficacy, but safety
concerns halted their development.24-27 The results of
1 phase 2B19 and 2 phase 320,21 clinical trials demonstrated that ubrogepant is well tolerated and effective for the acute treatment of migraine attacks. The
most common (≥2% of participants in any treatment
group) TEAEs in the ACHIEVE I phase 3 trial were
nausea, somnolence, and dry mouth and in the phase
3 ACHIEVE II trial were nausea and dizziness.20,21 No
serious AEs were reported within 48 hours postdose
in either trial. No participants discontinued because
of AEs and no hepatic safety signals were identified in
either trial.
Overall, data from this trial further support the
safety profile of ubrogepant. With regard to hepatic
safety, 2% (16/805) of participants randomized to
ubrogepant had increases in their ALT/AST ≥3× the
ULN versus 1% (4/397) of participants in the usual
care arm. There were no concerning hepatic safety findings and 13 of the 16 cases in the ubrogepant groups
were adjudicated as Unlikely Related to trial treatment.
Two cases were judged Possibly Related and 1 case was
judged Probably Related; however, confounding factors were noted in each case (increased alcohol and
acetaminophen use; dilated bile duct; and prednisone
use). These findings, along with the observation that all
aminotransferase elevations ≥3× ULN resolved in participants who continued ubrogepant dosing, indicate
that there were no clinically meaningful hepatic safety
signals for ubrogepant in this trial. These data also help
to confirm findings from the dedicated hepatic safety
trial in healthy volunteers, where ubrogepant was
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found to be safe and well tolerated, with no hepatic
safety signals noted following high-frequency dosing
for 12 weeks.28
The efficacy of ubrogepant has been demonstrated
in 2 phase 3, multicenter, randomized, double-blind,
placebo-controlled single-attack trials (ACHIEVE I
and II).20,21 The percentage of participants reporting
pain freedom 2 hours post-initial dose was significantly
greater in the ubrogepant arms than the placebo arms of
both trials. In addition, the proportion of participants
reporting absence of the most bothersome migraineassociated symptom (photophobia, phonophobia, or
nausea) at 2 hours was greater in the ubrogepant arms
than the placebo arms of both trials. While the present
trial was designed as a long-term safety trial, efficacy
measures were collected for the ubrogepant treatment
arms.29 Participants reported pain freedom at 2 hours
for an average of 23% of attacks treated with ubrogepant
50 mg and 25% of attacks treated with ubrogepant
100 mg. Pain relief at 2 hours was achieved for 65% of
attacks treated with ubrogepant 50 mg and 68% treated
with ubrogepant 100 mg. Efficacy was maintained over
the 1-year trial period.
As with most trials, this trial does have some limitations that may impact the interpretation and generalizability of the data. First, exclusion of those with
certain diseases, disease states, and clinically significant
conditions as outlined in the methods section may limit
these data from being reflective of real-world experience. However, inclusion of participants with ALT/AST
elevations ≤1.5× the ULN and bilirubin <1.5 mg/dL
increases the generalizability of the data. Second, differences in participant populations and trial designs
limit the ability to compare safety profiles of different acute treatment options for migraine. In particular, headache pain of any severity was allowed to be
treated in this trial, which may not be consistent with
other reported trials. Third, commonly reported AEs
of nausea and dizziness can be symptoms associated
with a migraine attack, making it is difficult to discern the causality of these AEs. Finally, the usual care
arm was included to identify possible fluctuations in
hepatic laboratory parameters to help contextualize the
hepatic safety data. Interpretation of the AE data in
the usual care arm, and comparison to the ubrogepant
arms, is limited as the usual care arm consisted of
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participants who had been on and had tolerated their
medication; therefore, AE rates do not reflect the introduction of a new treatment. The usual care arm of the
present study does, however, reflect similar AE rates
observed in other long-term safety studies conducted
on alternative acute treatments for migraines, in which
overall AE rates ranged from 45 to 68% of patients for
up to an 18-month period.30-32

CONCLUSIONS
Long-term intermittent use of ubrogepant 50 and
100 mg given as 1 or 2 doses per attack for the acute
treatment of migraine was safe and well tolerated, as
indicated by a low incidence of TEAEs and low rate of
SAEs and discontinuations due to AEs, in this 1-year
trial.
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